TransMedics Group, Inc. (TMDX) Average Gross Margin
The current gross margin for TransMedics Group, Inc. (TMDX) is N/A as of Saturday, June 20, 2026, shown against its trailing averages.
Average Gross Margin Chart
TMDX Gross Margin Averages
GROSS MARGIN CURRENT
N/A
GROSS MARGIN TTM
59.64%
GROSS MARGIN 3Y
63.22%
GROSS MARGIN 5Y
64.62%
GROSS MARGIN 10Y
53.06%
GROSS MARGIN 15Y
53.06%
GROSS MARGIN 20Y
53.06%
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein